Efficacy of ST1959 in murine models of autoimmunity and insights into its peculiar immunomodulatory profile

International Journal of Immunotherapy

Volumn 19, Issue 1, 2003, Pages 1-10

  Ruggiero, Vito ^a   Albertoni, C ^a   Rosi, A ^a   Leoni, B ^a   Carminati, P ^a   De Santis, R ^a  

^a Prassis Sigma Tau Research Institute   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3 (2 ETHYLPHENYL) 5 (3 METHOXYPHENYL) 1H 1,2,4 TRIAZOLE; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; COLLAGEN; CONTRACEPTIVE AGENT; CYCLOSPORIN A; IMMUNOMODULATING AGENT; LEFLUNOMIDE; ST 1959; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; CELL COUNT; CELL PROLIFERATION; CELL SUBPOPULATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG ACTIVITY; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; FEMALE; IMMUNOMODULATION; LYMPHOID ORGAN; MALE; MITOGENESIS; MOUSE; MOUSE STRAIN; NONHUMAN; ORGAN WEIGHT; RAT; RAT STRAIN; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SEROLOGY; SURVIVAL; SYSTEMIC LUPUS ERYTHEMATOSUS; THYMOCYTE; THYMUS; TREATMENT OUTCOME;

EID: 0347917309     PISSN: 02559625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Galliani G., Assandri A., Gallico L., et al. A new non-hormonal pregnancy terminating agent. Contraception, 23, 163, 1981.
2. Mistrello G., Galliani G., Assandri A., Filippeschi S., Bassi L. Immunological profile of DL111-IT a new immunosuppressant agent. Immunopharmacology, 10, 163, 1985.
3. Mok C.C., Lau C.S. Pathogenesis of systemic lupus erythematosus. J. Clin. Pathol., 56, 481, 2003.
4. Tsao B.P., Ebling F.M., Roman C., et al. Structural characteristics of the variable regions of immunoglobulin genes encoding a pathogenic autoantibody in murine lupus. J. Clin. Invest., 85, 530, 1990.
5. Stoll M.L., Gavalchin J. Systemic lupus erythematosus-messages from experimental models. Rheumatology, 39, 18, 2000.
6. Courtenay J.S., Dallman M.J., Dayan A.D., Martin A., Mosedale B. Immunization against heterologous type II collagen induces arthritis in mice. Nature, 283, 666, 1980.
7. Brennan F.M., Maini R.N., Feldmann M. Role of pro-inflammatory cytokines in rheumatoid arthritis. Springer Semin. Immunopathol., 20, 133, 1998.
8. Cohen P.L., Eisenberg R.A. Lpr and gld: Single gene models of systemic autoimmunity and lymphoproliferative disease. Annu. Rev. Immunol., 9, 243, 1991.
9. Theofilopoulos A.N., Prud'Homme G.J., Dixon F.J. Autoimmune aspects of systemic lupus erythematosus. Concepts Immunopathol., 1, 190, 1985.
10. Jiménez S., Cervera R., Font J., Ingelmo M. The epidemiology of systemic lupus erythematosus. Clin. Rev. Allergy Immunol., 25, 3, 2003.
11. Wooley P.H., Whalen J.D., Warner L.M., Losten M.K., Chapdelaine J.M. Type II collagen induced arthritis in mice. V. The role of the spleen cell response in the immune and arthrogenic reaction to type II collagen. J. Rheumatol., 16, 1192, 1989.
12. Smolen J.S., Steiner G. Therapeutic strategies for rheumatoid arthritis. Nat. Rev. Drug Discov., 2, 473, 2003.
13. Gescuk B.D., Davis J.C. Jr. Novel therapeutic agents for systemic lupus erythematosus. Curr. Opin. Rheumatol., 14, 515, 2002.
14. Saravanan V., Hamilton J. Advances in the treatment of rheumatoid arthritis: Old versus new therapies. Expert. Opin. Pharmacother., 3, 845, 2002.
15. Moynihan R. FDA officials argue over safety of new arthritis drug. Br. Med. J., 326, 565, 2003.
16. Sanders S., Harisdangkul V. Leflunomide for the treatment of rheumatoid arthritis and autoimmunity. Am. J. Med. Sci., 323, 190, 2002.
17. Herrmann M.L., Schleyerbach R., Kirschbaum B.J. Leflunomide: An immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases. Immunopharmacology, 47, 273, 2000.
18. Aletaha D., Smolen J.S. Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study. J. Rheumatol., 29, 1631, 2002.
19. Jorgensen K.A., Koefoed-Nielsen P.B., Karamperis N. Calcineurin phosphatase activity and immunosuppression. A review on the role of calcineurin phosphatase activity and the immunosuppressive effect of cyclosporin A and tacrolimus. Scand. J. Immunol., 57, 93, 2003.
20. Amasaki Y., Masuda E.S., Imamura R., Arai K., Arai N. Distinct NFAT family proteins are involved in the nuclear NFAT-DNA binding complexes from human thymocyte subsets. J. Immunol., 160, 2324, 1998.
21. Anderson G., Moore N.C., Owen J.J., Jenkinson E.J. Cellular interactions in thymocyte development. Annu. Rev. Immunol., 14, 73, 1996.
22. Basson M.A., Zamoyska R. The CD4/CD8 lineage decision: Integration of signalling pathways. Immunol. Today, 21, 509, 2000.
23. Jenkins M.K., Schwartz R.H., Pardoll D.M. Effects of cyclosporine A on T-cell development and clonal deletion. Science, 241, 1655, 1988.
24. Gao E.K., Lo D., Cheney R., Kanagawa O., Sprent J. Abnormal differentiation of thymocytes in mice treated with cyclosporin A. Nature 336, 176, 1988.
25. Damoiseaux J.G., Beijleveld L.J., Van Breda Vriesman P.J., Multiple effects of cyclosporin A on the thymus in relation to T-cell development anod autoimmunity. Clin. Immunol. Immunopathol., 82, 197, 1997.